25Apr 2022
The pan‐JAK inhibitor delgocitinib in a cream formulation demonstrates dose response in chronic hand eczema in a 16‐week randomized phase IIb trial

The pan‐JAK inhibitor delgocitinib in a cream formulation demonstrates dose response in chronic hand eczema in a 16‐week randomized phase IIb trial

This trial assessed the dose-response, efficacy and safety of delgocitinib cream in CHE. In this double-blind, phase IIb dose-ranging trial, adults with CHE and a recent history of inadequate response or contraindication to topical corticosteroids were randomized to delgocitinib cream 1, 3, 8, 20 mg g–1 or vehicle treatment twice daily for 16 weeks. The primary endpoint was the Investigator’s Global Assessment for CHE (IGA-CHE) treatment success. Patients (n = 258) were randomized 1 : 1 : 1 : 1 : 1 to delgocitinib cream 1, 3, 8, 20 mg g–1 or vehicle. A significant dose-response relationship was established for IGA-CHE (P < 0.025). Delgocitinib 8 and 20 mg g–1 showed a treatment effect against the vehicle (P < 0.001). Similarly, there were improvements in HECSI, itch and pain NRS scores, and PaGA. In this trial, delgocitinib cream showed a dose-response relationship in efficacy and was well tolerated.

  • #dermatology

Like

Save

Share